泰林生物
(300813)
| 流通市值：19.55亿 | | | 总市值：31.15亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 70,063,538.95 | 339,538,843.84 | 213,188,852.61 | 145,825,607.2 |
| 营业收入 | 70,063,538.95 | 339,538,843.84 | 213,188,852.61 | 145,825,607.2 |
| 二、营业总成本 | 66,596,113.34 | 329,644,577.8 | 201,314,970.5 | 132,729,520.4 |
| 营业成本 | 34,813,477.4 | 185,246,081.46 | 101,066,952.22 | 70,109,926.46 |
| 税金及附加 | 713,219.92 | 5,124,925.31 | 2,086,673.21 | 1,445,942.52 |
| 销售费用 | 9,044,005.62 | 46,891,489.75 | 29,484,843.37 | 18,594,428.14 |
| 管理费用 | 8,668,565.5 | 39,289,047.55 | 25,452,962.51 | 15,885,481.21 |
| 研发费用 | 14,071,990.95 | 57,209,256.09 | 49,120,227.85 | 30,976,719.59 |
| 财务费用 | -715,146.05 | -4,116,222.36 | -5,896,688.66 | -4,282,977.52 |
| 其中:利息费用 | - | - | - | 0 |
| 其中:利息收入 | -1,128,383.1 | 4,925,309.76 | 6,323,595.52 | 4,462,895.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 20,441.21 | 542.69 | - |
| 加:投资收益 | -3,198.03 | 4,356,675.93 | 683,184.01 | -5,502.22 |
| 资产处置收益 | - | - | 0 | - |
| 资产减值损失(新) | - | -3,963,381.82 | 221,549.05 | -27,112.65 |
| 信用减值损失(新) | 459,410.88 | -1,290,716.19 | -1,457,109.13 | -2,090,608.33 |
| 其他收益 | 1,451,122.45 | 7,920,808.15 | 4,299,946.93 | 2,660,840.59 |
| 四、营业利润 | 5,374,760.91 | 16,938,093.32 | 15,621,995.66 | 13,633,704.19 |
| 加:营业外收入 | 1,507.03 | 396,198.12 | 24,240.7 | 19,066.82 |
| 减:营业外支出 | 93,667.84 | 595,574.93 | 570,628.42 | 554,738.54 |
| 五、利润总额 | 5,282,600.1 | 16,738,716.51 | 15,075,607.94 | 13,098,032.47 |
| 减:所得税费用 | 442,289.27 | 452,641.81 | 552,571.33 | -244,678.6 |
| 六、净利润 | 4,840,310.83 | 16,286,074.7 | 14,523,036.61 | 13,342,711.07 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,840,310.83 | 16,286,074.7 | 14,523,036.61 | 13,342,711.07 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,840,310.83 | 16,485,445.79 | 14,723,274.72 | 13,542,949.18 |
| 少数股东损益 | - | -199,371.09 | -200,238.11 | -200,238.11 |
| 扣除非经常损益后的净利润 | 4,205,524.73 | 10,527,649.45 | 13,048,665.2 | 13,203,834.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.14 | 0.12 | 0.11 |
| (二)稀释每股收益 | 0.04 | 0.14 | 0.11 | 0.11 |
| 九、综合收益总额 | 4,840,310.83 | 16,286,074.7 | 14,523,036.61 | 13,342,711.07 |
| 归属于母公司股东的综合收益总额 | 4,840,310.83 | 16,485,445.79 | 14,723,274.72 | 13,542,949.18 |
| 归属于少数股东的综合收益总额 | - | -199,371.09 | -200,238.11 | -200,238.11 |
| 公告日期 | 2026-04-30 | 2026-03-27 | 2025-10-27 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |